Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism

Hematology Journal

Volumn 3, Issue 6, 2002, Pages 311-314

  Svensson, Per ^a   Södermark, Anna ^a   Schulman, Sam ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Intensity; Recurrence; Thrombophilia; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FOLLOW UP; HEMATOMA; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; MALE; MEDICAL DECISION MAKING; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZATION; RECURRENT DISEASE; REGISTER; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; FAMILY HEALTH; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; QUESTIONNAIRES; RECURRENCE; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0036975302     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200193     Document Type: Article

References (20)

1. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114 (Suppl): 445-469.
2. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-Å, Hjorth M, Linder O, Boberg J and The DURAC Trial Study Group. A comparison of six weeks with six months of oral anticoagulation therapy after a first episode of venous thromboembolism. N Eng J Med 1995; 332: 1661-1665.
3. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lessons. Am J Med 1989; 87: 153-159.
4. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 (Suppl): 511-523.
5. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. Arch Int Med 1993; 153: 1557-1562.
6. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994; 120: 897-902.
7. Fihn SD, McDonell M, Martin D. Risk factors for complications of chronic anticoagulation. Ann Int Med 1993; 118: 511-520.
8. MacCallum PK, Brennan PJ, Meade TW. Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease. Arch Int Med 2000; 160: 2462-2468.
9. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (Cochrane Review). In: The Cochrane Library. Issue 4. Oxford: Update Software, 2000.
10. Ridker PM for the PREVENT Investigators. Long-term, low-dose warfarin among venous thrombosis patients, with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 1998; 3: 67-73.
11. Klein KL, Berdeaux DH, Milhollen JD, Hilden JT, Oberneuemann NJ, Koch MA, et al. Equal effectiveness of very-low-intensity anticoagulation and standard low-intensity anticoagulation: a pilot study. Southern Med J 1995; 88: 1136-1139.
12. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
13. Schulman S. Duration of oral anticoagulant treatment following deep vein thrombosis-the longer, the better? Thrombosis Haemostasis 2001; 86 (Suppl): SY2415 (Abstract).
14. Schulman S, Svenungsson E, Granqvist S and the Duration of Anticoagulation Trial Study Group. The predictive value of anticardiolipin antibodies in patients with venous thromboembolism. Am J Med 1998; 104: 332-338.
15. van den Belt AGM, Sanson B-J, Simioni P, Prandoni P, Buller HR, Girolami A, Prins MH. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Int Med 1997; 157: 2227-2232.
16. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H and the DURAC Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thrombosis Haemostasis 1999; 81: 684-689.
17. Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thrombosis Haemostasis 1998; 80: 566-569.
18. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Eng J Med 2000; 343: 457-462.
19. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. J Am Med Assoc 1983; 249: 1743-1745.
20. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Int Med 2000; 133: 687-695.